REGENXBIO Revenue and Competitors

Claim your profile

Location

#7926

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • REGENXBIO's estimated annual revenue is currently $93.1M per year.(i)
  • REGENXBIO received $201.8M in venture funding in August 2018.
  • REGENXBIO's estimated revenue per employee is $206,978
  • REGENXBIO's total funding is $638.2M.
  • REGENXBIO's current valuation is $1.2B. (January 2022)

Employee Data

  • REGENXBIO has 450 Employees.(i)
  • REGENXBIO grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.1M400%$17.5MN/A
#2
$4.4M57-49%$10.5MN/A
#3
$18.3M1180%$69.4MN/A
#4
$12.6M8129%N/AN/A
#5
$2.6M4146%N/AN/A
#6
$1.2M160%$40MN/A
#7
$6.8M44N/AN/AN/A
#8
$2.2M3431%N/AN/A
#9
$1.6M10-23%N/AN/A
#10
$1.4M180%$34.7MN/A

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and thirdparty NAV Technology Platform licensees.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$638.2M

Total Funding

450

Number of Employees

$93.1M

Revenue (est)

20%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

REGENXBIO News

2022-04-19 - Regenxbio: Is The Ultimate Catalyst Coming?

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the...

2022-04-19 - REGENXBIO Announces Presentation at Chardan's 6th ...

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential...

2022-04-13 - REGENXBIO (NASDAQ:RGNX) Upgraded by Zacks ...

REGENXBIO (NASDAQ:RGNX) Upgraded by Zacks Investment Research to “Buy”. Posted by admin on Apr 15th, 2022. Share on Twitter Share on Facebook Share on...

2021-04-27 - REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting

ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapy's 24th Annual Meeting taking place from May 11 to 14, 2021, in virtual format. Presentati ...

2021-02-01 - REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021

ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking place virtually from February 8 through 12, 2021. The oral presentations include interim results ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$89.8M5055%$117.6M
#2
$109M50737%N/A
#3
$116M512-1%$165.9M
#4
$117.7M523N/AN/A
#5
$35M55124%N/A

REGENXBIO Funding

DateAmountRoundLead InvestorsReference
2013-11-11$7.9MUndisclosedArticle
2015-01-22$30.0MCVenrockArticle
2015-05-21$70.5MDVivo CapitalArticle
2018-08-09$175.0MUndisclosedMorgan StanleyArticle
2018-08-13$201.8MUndisclosedMorgan StanleyArticle